Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline for Prevention of Paralysis in Spinal Cord Trauma and Tumors
NCT01813240Phase 3Unknown
- Sponsor
- Hadassah Medical Organization
- Start
- May 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of minocycline in spinal cord injury (SCI) and spinal cord neoplasm (SCT) (4 arms), sponsored by Hadassah Medical Organization. Primary endpoint: Efficacy of administrating minocycline in minimizing the neurological damage at 6 months. Status: unknown.
02
Drugs
minocycline
03
Conditions
spinal cord injury (SCI)spinal cord neoplasm (SCT)
Beyond the preview
Go deeper on NCT01813240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813240.